TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32615110

Group type: COMPARATOR
Intervention: Weekly paclitaxel (80 mg/m2) with carboplatin AUC5 or AUC6 every 3 weeks (group 2)
Number of subjects: 1566

Group type: COMPARATOR
Intervention: Weekly paclitaxel (80 mg/m2) with carboplatin AUC2 weekly (group 3)
Number of subjects: 1566

Group type: EXPERIMENTAL
Intervention: 3-weekly chemotherapy (carboplatin AUC5 or AUC6 and 175 mg/m2 intravenous paclitaxel) (group 1)
Number of subjects: 1566
Study: 34417553

Group type: EXPERIMENTAL
Intervention: Take CHARGE (n=85)
Number of subjects: 171

Group type: COMPARATOR
Intervention: PE Planners (n=86)
Number of subjects: 171
Study: 33019896

Group type: EXPERIMENTAL
Intervention: Presence of diabetic retinopathy (DR) at baseline
Number of subjects: 2828

Group type: COMPARATOR
Intervention: No diabetic retinopathy (DR) at baseline
Number of subjects: 2828
Study: 34501553

Group type: EXPERIMENTAL
Intervention: AerG (aerobic group)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: IntG (intensity group)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: ComG (combined group)
Number of subjects: 102

Group type: COMPARATOR
Intervention: CG (control group)
Number of subjects: 102
Study: 33888772

Group type: EXPERIMENTAL
Intervention: linagliptin/metformin 2.5/850 mg twice daily (LM group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: metformin 850 mg twice daily (M group)
Number of subjects: 31
Study: 33308425

Group type: EXPERIMENTAL
Intervention: Cabotegravir plus rilpivirine long‐acting every 8 weeks (cabotegravir 600 mg plus rilpivirine 900 mg)
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Cabotegravir plus rilpivirine long‐acting every 4 weeks (cabotegravir 400 mg plus rilpivirine 600 mg)
Number of subjects: 1045
Study: 32312288

Group type: EXPERIMENTAL
Intervention: Incident delirium
Number of subjects: 1495

Group type: EXPERIMENTAL
Intervention: Days spent with delirium
Number of subjects: 1495

Group type: EXPERIMENTAL
Intervention: Days spent with coma
Number of subjects: 1495

Group type: EXPERIMENTAL
Intervention: Days spent with delirium or coma
Number of subjects: 1495
Study: 35773357

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Combination of Tadalafil 5 mg and Silodosin 8 mg
Number of subjects: 308
Study: 34177933

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy combined with pembrolizumab
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy and immunotherapy
Number of subjects: 1
Study: 35685986

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg intravenously before surgery
Number of subjects: 64

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 64
Study: 32880094

Group type: EXPERIMENTAL
Intervention: Tailored work-related support intervention (3 psychosocial meetings before treatment)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Tailored work-related support intervention
Number of subjects: 88
Study: 36201701

Group type: EXPERIMENTAL
Intervention: Extended Osteotomy Guide (EOG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Traditional Osteotomy Guide (TOG)
Number of subjects: 28
Study: 33430785

Group type: EXPERIMENTAL
Intervention: Multi-component, non-pharmacological intervention to prevent and reduce sleep problems
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Multi-component, non-pharmacological intervention
Number of subjects: 24
Study: 36244652

Group type: EXPERIMENTAL
Intervention: High-dose losartan (150 mg/d)
Number of subjects: 3834

Group type: COMPARATOR
Intervention: Low-dose losartan (50 mg/d)
Number of subjects: 3834
Study: 32479559

Group type: EXPERIMENTAL
Intervention: Struck singing bowl
Number of subjects: 58

Group type: COMPARATOR
Intervention: Silent singing bowl
Number of subjects: 58
Study: 33419660

Group type: EXPERIMENTAL
Intervention: Treatment Initiation Program
Number of subjects: 189

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 189
Study: 35676679

Group type: EXPERIMENTAL
Intervention: Multi-setting lifestyle intervention (school-, family-, and community-based programs)
Number of subjects: 2374

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2374

Group type: EXPERIMENTAL
Intervention: Multi-setting lifestyle intervention
Number of subjects: 2374
Study: 34755519

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily for 25 to 45 days
Number of subjects: 16496

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16496
Study: 32164687

Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation program supported by information and communication technologies
Number of subjects: 0
Study: 34052865

Group type: EXPERIMENTAL
Intervention: Endoscopic cartilage–perichondrium modified over‐underlay myringoplasty (MOUM)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Endoscopic cartilage–perichondrium transtympanic underlay alone myringoplasty (TUAM)
Number of subjects: 99
Study: 33179856

Group type: EXPERIMENTAL
Intervention: pre‐BAV (pre-dilatation)
Number of subjects: 171

Group type: COMPARATOR
Intervention: no‐BAV (no pre-dilatation)
Number of subjects: 171
Study: 35659791

Group type: EXPERIMENTAL
Intervention: Ultraviolet-C (UV-C) light treatment with a room decontamination device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium hypochlorite delivered via an electrostatic sprayer
Number of subjects: 0
Study: 33243308

Group type: EXPERIMENTAL
Intervention: Social Network Intervention (SNI)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Active Control
Number of subjects: 451

Group type: COMPARATOR
Intervention: Control Condition
Number of subjects: 451
Study: 36227593

Group type: EXPERIMENTAL
Intervention: EX (multicomponent exercise program)
Number of subjects: 120

Group type: COMPARATOR
Intervention: BAT (balance and tone control group)
Number of subjects: 120
Study: 33793043

Group type: EXPERIMENTAL
Intervention: Novel PRP (single spin and low-temperature activation)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional PRP (double spin and calcium activation)
Number of subjects: 21
Study: 32453759

Group type: EXPERIMENTAL
Intervention: dezocine (1 mg/kg) with sufentanil (1.3 μg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: sufentanil (2.3 μg/kg)
Number of subjects: 120
Study: 35961250

Group type: EXPERIMENTAL
Intervention: idursulfase‐IT 10 mg once a month plus IV idursulfase (0.5 mg/kg) once a week
Number of subjects: 56

Group type: COMPARATOR
Intervention: early idursulfase‐IT
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: idursulfase‐IT
Number of subjects: 56
Study: 35668438

Group type: EXPERIMENTAL
Intervention: Video-led educational intervention (12-minute video education on influenza and its vaccination)
Number of subjects: 350
Study: 35987809

Group type: EXPERIMENTAL
Intervention: Nutritional supplements, protein‐rich, high‐fiber diet, care by a professional nutritionist
Number of subjects: 62
Study: 35337843

Group type: EXPERIMENTAL
Intervention: Hybrid training system (HTS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sensory transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 28
Study: 32303765

Group type: EXPERIMENTAL
Intervention: EE + DNG
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: EV + DNG
Number of subjects: 59

Group type: COMPARATOR
Intervention: DNG only
Number of subjects: 59
Study: 36075592

Group type: EXPERIMENTAL
Intervention: Lingnan Chen's acupuncture (delivered at Shenshu (BL 23), Pishu (BL 20), Guanyuan (CV 4), Sanyinjiao (SP 6), etc.), once every two days, three times a week for 12 weeks.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Calcitriol soft capsules (0.25 μg each time, twice a day for 12 weeks).
Number of subjects: 70
Study: 33878192

Group type: EXPERIMENTAL
Intervention: Transdermal CO2 gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo gel (ultrasound gel)
Number of subjects: 20
Study: 35043534

Group type: EXPERIMENTAL
Intervention: Video with a warm expert
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Video displaying a neutral expert
Number of subjects: 68

Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 68
Study: 33397297

Group type: EXPERIMENTAL
Intervention: Teaching involving whole-body movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teaching involving hand movements (i.e. arms and hands)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teaching involving minimal motor movements (i.e. seated on a chair using paper and pencil)
Number of subjects: 0
Study: 36038580

Group type: EXPERIMENTAL
Intervention: Tobacco heating products (THPs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional cigarettes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicotine replacement therapy (NRT)
Number of subjects: 0
Study: 33730885

Group type: EXPERIMENTAL
Intervention: Collaborative chronic care model (CCM) implementation support for 1 year
Number of subjects: 9

Group type: COMPARATOR
Intervention: Post-implementation support period
Number of subjects: 9
Study: 36202236

Group type: EXPERIMENTAL
Intervention: Standard Message
Number of subjects: 1235

Group type: EXPERIMENTAL
Intervention: COVID‐19 Vaccine Message
Number of subjects: 1235

Group type: COMPARATOR
Intervention: No Message (control)
Number of subjects: 1235
Study: 33127204

Group type: EXPERIMENTAL
Intervention: Normal-angle group (N group)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: High-angle group (H group)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Both groups (N and H)
Number of subjects: 43
Study: 32782181

Group type: EXPERIMENTAL
Intervention: Option Grid
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Picture Option Grid
Number of subjects: 311

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 311
Study: 34962157

Group type: EXPERIMENTAL
Intervention: Me & My Wishes videos shared with family
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Me & My Wishes videos shared with staff
Number of subjects: 50
Study: 33385534

Group type: EXPERIMENTAL
Intervention: Rubber dam isolation
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Lack of marginal adaptation of restoration
Number of subjects: 38

Group type: COMPARATOR
Intervention: Cotton roll isolation
Number of subjects: 38
Study: 34479797

Group type: EXPERIMENTAL
Intervention: Oral vitamin D supplementation (400-1600 IU/d)
Number of subjects: 63
Study: 35551318

Group type: EXPERIMENTAL
Intervention: Daily oral tablets
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Monthly vaginal rings
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Monthly dual injections
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Placebo products
Number of subjects: 127
Study: 32203571

Group type: EXPERIMENTAL
Intervention: SDT-based psychological intervention + RA-tailored exercise program (n = 59)
Number of subjects: 115

Group type: COMPARATOR
Intervention: RA-tailored exercise program only (n = 56)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: SDT-based psychological intervention
Number of subjects: 115
Study: 32467108

Group type: EXPERIMENTAL
Intervention: Electronic best practice alert (BPA) for telemetry; triggered 1042 alerts during the study.
Number of subjects: 558

Group type: COMPARATOR
Intervention: Control group (no BPA alerts).
Number of subjects: 558
Study: 34456030

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 266

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Olanzapine (Phase II)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Clozapine (Phase III)
Number of subjects: 266
Study: 33201577

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 35581642

Group type: EXPERIMENTAL
Intervention: Parents' feeding practices and physical activity facilitation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Household resilience factors (secure housing and employment)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Parents' emotional and social wellbeing
Number of subjects: 70
Study: 33252964

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring intervention
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control
Number of subjects: 209
Study: 32253065

Group type: EXPERIMENTAL
Intervention: Intra-articular analgesia + Saphenous Nerve Block (SNB)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intra-articular analgesia + Placebo
Number of subjects: 70
Study: 35510562

Group type: EXPERIMENTAL
Intervention: Treatment (vaccine)
Number of subjects: 0
Study: 34153931

Group type: EXPERIMENTAL
Intervention: CA prediction nomogram
Number of subjects: 685
Study: 35742279

Group type: EXPERIMENTAL
Intervention: Online group (n = 19) - 40‐min trunk stabilization exercise sessions twice a week for six weeks via ZOOM
Number of subjects: 37

Group type: COMPARATOR
Intervention: Offline group (n = 18) - same program in person
Number of subjects: 37

Group type: COMPARATOR
Intervention: Comparison of left rectus abdominis thickness and Psychological/Baby and Relational/Spouse‐Partner subscale in maternal quality of life index
Number of subjects: 37
Study: 32147709

Group type: EXPERIMENTAL
Intervention: 12-month group-based exercise and behavior maintenance program
Number of subjects: 777

Group type: COMPARATOR
Intervention: Minimal Healthy Aging control intervention
Number of subjects: 777
Study: 35290742

Group type: EXPERIMENTAL
Intervention: Virtual Reality Training (VRT) program, 8 weeks, three 30-minute sessions per week using Xbox Kinect headset
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Virtual Reality Training (VRT) program
Number of subjects: 25
Study: 34110614

Group type: EXPERIMENTAL
Intervention: 25 1-mg OM slow-release minitablets
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 25 1-mg OM fast-release minitablets
Number of subjects: 20

Group type: COMPARATOR
Intervention: 25-mg OM matrix MR tablet
Number of subjects: 20
Study: 36183099

Group type: EXPERIMENTAL
Intervention: EIT-guided individualized PEEP
Number of subjects: 540

Group type: COMPARATOR
Intervention: Single PEEP (PEEP = 6 cmH2O)
Number of subjects: 540
Study: 34237987

Group type: EXPERIMENTAL
Intervention: Contralateral S1 nerve root transfer
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional treatments (non-surgical group)
Number of subjects: 40
Study: 32867832

Group type: EXPERIMENTAL
Intervention: Parent Child Interaction Therapy ‐ Toddler
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Circle of Security‐ Parenting™
Number of subjects: 90

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 90
Study: 35316689

Group type: EXPERIMENTAL
Intervention: Nabiximols
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 34975132

Group type: EXPERIMENTAL
Intervention: Phyllanthus niruri
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 36399194

Group type: EXPERIMENTAL
Intervention: LDAC plus nintedanib
Number of subjects: 30

Group type: COMPARATOR
Intervention: LDAC plus placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LDAC plus nintedanib (in r/r AML)
Number of subjects: 30

Group type: COMPARATOR
Intervention: LDAC plus placebo (in r/r AML)
Number of subjects: 30
Study: 32556730

Group type: EXPERIMENTAL
Intervention: Haemoblock (15 ml retromuscularly and 15 ml subcutaneously)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (no Haemoblock)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Haemoblock
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control
Number of subjects: 66
Study: 32654395

Group type: EXPERIMENTAL
Intervention: Online CPT delivery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: F2F CPT delivery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no program)
Number of subjects: 30
Study: 35518935

Group type: EXPERIMENTAL
Intervention: Hydrocortisone dose of 0.2-0.3 mg/kg/day
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Hydrocortisone dose of 0.4-0.6 mg/kg/day
Number of subjects: 52
Study: 32385676

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) kit
Number of subjects: 272
Study: 35785344

Group type: EXPERIMENTAL
Intervention: Digital integrated care using the migraine app M-sense combined with a communication platform (online consultations and medically moderated patient forum)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 33539713

Group type: EXPERIMENTAL
Intervention: Navigation app task (app-task)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Map task
Number of subjects: 12

Group type: COMPARATOR
Intervention: Photo-language task
Number of subjects: 12
Study: 33028263

Group type: EXPERIMENTAL
Intervention: Worry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anxiety disorders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anorexia nervosa (AN)
Number of subjects: 0
Study: 34546554

Group type: EXPERIMENTAL
Intervention: IBS-QoL questionnaire
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: EQ-5D-5L utility score
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: CLAD model 4 (total IBS-QoL score and squared IBS-SSS)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: IBS-QoL and EQ-5D-5L
Number of subjects: 283
Study: 34732432

Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy (62 patients)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Non-anticoagulation treatment (446 patients)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: All patients (506 patients)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Preoperative anticoagulation therapy
Number of subjects: 506
Study: 35189937

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT) consisting of 14 teleconference sessions with the child and parents, supported by an app for symptom assessment and wristband monitoring.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting list control group receiving treatment after a 16-week waiting period.
Number of subjects: 60
Study: 34076179

Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 25% oral glucose
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 25% oral glucose combined with non-nutritive sucking
Number of subjects: 34
Study: 32614037

Group type: EXPERIMENTAL
Intervention: Brown marmorated stink bug adults and nymphs feeding (1.7‐4.0 feeding sites per fruit)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no brown marmorated stink bug)
Number of subjects: 6
Study: 33499714

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Flunarizine and Topiramate
Number of subjects: 66
Study: 34111902

Group type: EXPERIMENTAL
Intervention: Response Adaptive Block Randomization (RABR) design
Number of subjects: 0
Study: 33207841

Group type: EXPERIMENTAL
Intervention: 8‐figure shoulder brace
Number of subjects: 33

Group type: COMPARATOR
Intervention: No shoulder brace (control)
Number of subjects: 33
Study: 34196852

Group type: EXPERIMENTAL
Intervention: Povidone-iodine irrigation of oral cavity for 3 min before operation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Chlorhexidine gluconate irrigation of oral cavity for 3 min before operation
Number of subjects: 24
Study: 33512412

Group type: EXPERIMENTAL
Intervention: Response-adapted therapy including 4 cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide with involved-field radiation therapy (RT)
Number of subjects: 1711

Group type: COMPARATOR
Intervention: Response-adapted therapy including 4 cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide without involved-field radiation therapy (RT)
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: Additional chemotherapy with dexamethasone, etoposide, cisplatin, and cytarabine for patients with slow early response
Number of subjects: 1711
Study: 32779096

Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA 50 U
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA 25 U
Number of subjects: 61

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 61
Study: 34990581

Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban regimen (HDER) 60 mg/reduced 30 mg
Number of subjects: 21105

Group type: EXPERIMENTAL
Intervention: Lower-dose edoxaban regimen (LDER) 30 mg/reduced 15 mg
Number of subjects: 21105

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105
Study: 35221703

Group type: EXPERIMENTAL
Intervention: Bilastine (standard dose)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Fexofenadine (standard dose)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Levocetirizine (standard dose)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Bilastine (up-dosing)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Fexofenadine (up-dosing)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Levocetirizine + Hydroxyzine (combination)
Number of subjects: 110
Study: 35962371

Group type: EXPERIMENTAL
Intervention: Serious game-based cognitive training (CCT)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Passive wait list control
Number of subjects: 162

Group type: COMPARATOR
Intervention: Active control (watching documentaries)
Number of subjects: 162
Study: 33954789

Group type: EXPERIMENTAL
Intervention: Zoledronic Acid (ZA) with calcium and vitamin D; 5 infusions (0.025 mg/kg at months 0 and 3, 0.05 mg/kg at months 6, 12, and 18)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Calcium and vitamin D alone (Control)
Number of subjects: 62
Study: 32548775

Group type: EXPERIMENTAL
Intervention: Culprit-lesion-only PCI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate multivessel PCI
Number of subjects: 0
Study: 33921063

Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 2286
Study: 33980185

Group type: EXPERIMENTAL
Intervention: Vitamin D and magnesium supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 36358447

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional detoxification
Number of subjects: 0